highperformr logo

Science 37's Overview

Total employees317
HeadquartersDurham
Founded2014

Science 37 is a research-focused organization pioneering a new era of clinical trial execution through its patient-centric, technology-driven Decentralized Clinical Trial (DCT) operating model. Their mission is to accelerate biomedical research and development by making clinical trial participation more accessible to patients, regardless of their geographical location. By leveraging in-house mobile nursing, telemedicine, and proprietary technology platforms, Science 37 aims to improve patient recruitment, retention, and data quality, ultimately speeding up the delivery of new treatments to market. In early 2024, Science 37 was acquired by eMed, further enhancing its capabilities to deliver end-to-end DCT solutions.

Where is Science 37's Headquarters?

Science 37 officeScience 37 officeScience 37 officeScience 37 office
*Images sourced via web search. Rights belong to original owners

HQ Function

The headquarters serves as the central hub for strategic leadership, global operations management, technology development, corporate governance, and administrative functions.

Notable Features:

The office is situated in a modern business park environment, designed to facilitate collaboration and innovation, benefiting from the rich ecosystem of the Research Triangle Park.

Work Culture:

The work culture at Science 37 emphasizes innovation, patient-centricity, collaboration, and agility. Employees are often driven by the mission to transform clinical research and improve patient access to trials. The environment encourages problem-solving and leveraging technology to overcome traditional research barriers.

HQ Significance:

Locating the headquarters in the Research Triangle Park area provides Science 37 with access to a highly skilled talent pool, proximity to leading research institutions and pharmaceutical companies, and a supportive business environment for life sciences and technology innovation.

Values Reflected in HQ: The headquarters' location and function reflect values such as innovation, strategic growth, operational excellence, and a commitment to advancing the field of decentralized clinical trials.

Location:

Science 37 supports clinical trial operations globally, with the capability to conduct studies in numerous countries. Their decentralized model and technology platform enable them to reach patients across diverse geographies, including North America, Europe, Latin America, and Asia-Pacific. This global reach allows for broader patient access, diverse population enrollment, and efficient trial management regardless of physical office locations.

Street Address:

600 Park Offices Drive, Suite 300

City:

Durham

State/Province:

North Carolina

Country:

USA

Science 37's Global Presence

Global Operations (Primarily Remote/Decentralized)

Address: N/A (Decentralized Model)

To support patient recruitment, trial conduct, and data collection globally, bringing trials directly to patients in their homes or local clinics. This includes operational support for North America, Europe, and Asia-Pacific regions.

Buying Intent Signals for Science 37

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Executive Team of Science 37

As of April 2025, Science 37' leadership includes:

David Coman - Chief Executive Officer
Mike Zaranek - Chief Commercial Officer
Christine Pellizzari - Chief Legal Officer
John R. W. Rountree - Chief Financial Officer
Troy Bryenton - Chief Technology Officer

Investors of Science 37

Science 37 has been backed by several prominent investors over the years, including:

eMed (Current Owner as of 2024)
Lux Capital (Prior to acquisition)
Redmile Group, LLC (Prior to acquisition)
GV (formerly Google Ventures) (Prior to acquisition)
PPD, Inc. (Prior to acquisition)
Novartis (Prior to acquisition)
Amgen (Prior to acquisition)
Glynn Capital Management (Prior to acquisition)

Executive New Hires/Exits in the Last 12 Months

Hire1
Exits1

The most significant executive event in the last 12 months was the acquisition of Science 37 by eMed, completed in January 2024. This led to a leadership transition with David Coman, formerly of eMed, becoming the CEO of Science 37.

Departures

David Casper, David Casper departed as CEO following the acquisition of Science 37 by eMed.

New Appointments:

David Coman, David Coman appointed as Chief Executive Officer of Science 37 after its acquisition by eMed.

Technology (Tech Stack) used by Science 37

Discover the tools Science 37 uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Science 37 Email Formats and Examples

Science 37 typically uses a standard corporate email format. The most common structures observed are [first].[last]@science37.com or [first_initial][last]@science37.com.

[first].[last]@science37.com or [first_initial][last]@science37.com

Format

john.doe@science37.com

Example

80%

Success rate

News and media

PR NewswireJanuary 22, 2024

eMed Completes Acquisition of Science 37, Pioneering the Future of Decentralized Clinical Trials

eMed announced the successful completion of its acquisition of Science 37 Holdings, Inc. This strategic move aims to combine eMed's telehealth and diagnostics capabilities with Science 37's expertise in decentralized clinical trials to create a comprehensive solution for modern clinical research....more

GlobeNewswireOctober 26, 2023

Science 37 Enters Definitive Agreement to be Acquired by eMed

Science 37 announced it had entered into a definitive agreement to be acquired by eMed, a digital healthcare company. The transaction was valued at approximately $38 million, with eMed set to acquire all outstanding shares of Science 37 for $5.75 per share in cash....more

Business WireMay 9, 2023

Science 37 Reports First Quarter 2023 Financial Results

Science 37 reported its financial results for the first quarter ended March 31, 2023, highlighting revenue growth and progress in expanding its decentralized clinical trial platform and services. This was one of their last earnings reports as a public company before the acquisition agreement....more

Highperformr’s free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Science 37, are just a search away.